medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2012; 11 (6)


Polycystic liver disease: a clinical review

Natasha Chandok N

Idioma: Ingles.
Referencias bibliográficas: 43
Paginas: 819-826
Archivo PDF: 171.97 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology [Review] 2010; 52: 2223-30.

  2. Everson GT, Helmke SM, Doctor B. Advances in management of polycystic liver disease. Expert review of gastroenterology & hepatology. [Review] 2008; 2: 563-76.

  3. Qian Q, Li A, King BF, Kamath PS, Lager DJ, Huston J 3rd, Shob C, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 2003; 37: 164-71.

  4. Temmerman F, Missiaen L, Bammens B, Laleman W, Cassiman D, Verslype C, van Pelt J, et al. Systematic review: the pathophysiology and management of polycystic liver disease. Alimentary pharmacology & therapeutics [Research Support, Non-U.S. Gov’t Review] 2011; 34: 702-13.

  5. Qian Q. Isolated polycystic liver disease. Advances in chronic kidney disease. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review] 2010; 17: 181-9.

  6. Drenth JP, Martina JA, Te Morsche RH, Jansen JB, Bonifacino JS. Molecular characterization of hepatocystin, the protein that is defective in autosomal dominant polycystic liver disease. Gastroenterology 2004; 126: 1819-27.

  7. Davila S, Furu L, Gharavi AG, Tian X, Onoe T, Qian Q, Li A, et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat Genet 2004; 36: 575-7.

  8. Li A, Davila S, Furu L, Qian Q, Tian X, Kamath PS, King BF, et al. Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease. Am J Hum Genet 2003; 72: 691-703.

  9. Gao H, Wang Y, Wegierski T, Skouloudaki K, Putz M, Fu X, Engel C, et al. PRKCSH/80K-H, the protein mutated in polycystic liver disease, protects polycystin-2/TRPP2 against HERP-mediated degradation. Hum Mol Genet 2010; 19: 16-24.

  10. Waanders E, Venselaar H, te Morsche RH, de Koning DB, Kamath PS, Torres VE, Somlo S, et al. Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63. Clin Genet 2010; 78: 47-56.

  11. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76: 149-68.

  12. Pirson Y. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Advances in chronic kidney disease. [Review] 2010; 17: 173-80.

  13. Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 1990; 11: 1033-7.

  14. Grunfeld JP, Albouze G, Jungers P, Landais P, Dana A, Droz D, Moynot A, et al. Liver changes and complications in adult polycystic kidney disease. Adv Nephrol Necker Hosp 1985; 14: 1-20.

  15. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, Baumgarten DA, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal- dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006; 1: 64-9.

  16. Bergmann C, Senderek J, Kupper F, Schneider F, Dornia C, Windelen E, Eggermann T, et al. PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD). Human mutation. [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S. Review] 2004; 23: 453-63.

  17. Zerres K, Hansmann M, Mallmann R, Gembruch U. Autosomal recessive polycystic kidney disease. Problems of prenatal diagnosis. Prenatal diagnosis. [Case Reports] 1988; 8: 215-29.

  18. Masyuk T, Masyuk A, LaRusso N. Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Current opinion in gastroenterology. [Review] 2009; 25: 265-71.

  19. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007; 132: 1104-16.

  20. Qian Q, Du H, King BF, Kumar S, Dean PG, Cosio FG, Torres VE. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol 2008; 19: 631-8.

  21. Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, et al. Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, Non-P.H.S.] 2010; 51: 1778-88.

  22. Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JP, Everson GT. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int 2008; 28: 264-70.

  23. Gallegos M, Bradly DP, Jakate SM. Image of the month. Polycystic liver disease leading to liver failure and transplantation. Clin Gastroenterol Hepatol [Case Reports] 2010; 8: A24.

  24. Kirchner GI, Rifai K, Cantz T, Nashan B, Terkamp C, Becker T, Strassburg C, et al. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl 2006; 12: 1268-77.

  25. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. JASN [Randomized Controlled Trial] 2010; 21: 1052-61.

  26. van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t] 2009; 137: 1661-8, e1-2.

  27. Arnold HL, Harrison SA. New advances in evaluation and management of patients with polycystic liver disease. Am J Gastroenterol 2005; 100: 2569-82.

  28. Gevers TJ, Drenth JP. Somatostatin analogues for treatment of polycystic liver disease. Curr Opin Gastroenterol [Review] 2011; 27: 294-300.

  29. Caroli A, Antiga L, Cafaro M, Fasolini G, Remuzzi A, Remuzzi G, Ruggenenti P. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. CJASN [Randomized Controlled Trial] 2010; 5: 783-9.

  30. Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, Hoffmann AL, et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Alimentary pharmacology & therapeutics. [Research Support, Non-U.S. Gov’t] 2012; 35: 266-74.

  31. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. JASN [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, P.H.S.] 2005; 16: 46-51.

  32. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med [Randomized Controlled Trial Research Support, Non-U.S. Gov’t] 2010; 363:820-9.

  33. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t] 2010; 363: 830-40.

  34. Nakaoka R, Das K, Kudo M, Chung H, Innoue T. Percutaneous aspiration and ethanolamine oleate sclerotherapy for sustained resolution of symptomatic polycystic liver disease: an initial experience. AJR 2009; 193: 1540-5.

  35. Kairaluoma MI, Leinonen A, Stahlberg M, Paivansalo M, Kiviniemi H, Siniluoto T. Percutaneous aspiration and alcohol sclerotherapy for symptomatic hepatic cysts. An alternative to surgical intervention. Ann Surg 1989; 210: 208-15.

  36. Nagorney DM, Schnelldorfer T, Torres VE, Rosen CB. Resection and Fenestration for Symptomatic Polycystic Liver Disease. Ann Surg 2011.

  37. van Keimpema L, Drenth JP. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg [Comment Letter] 2011; 253: 419; author reply 20.

  38. Aussilhou B, Doufle G, Hubert C, Francoz C, Paugam C, Paradis V, Farges O, et al. Extended liver resection for polycystic liver disease can challenge liver transplantation. Ann Surg 2010; 252: 735-43.

  39. Arrazola L, Moonka D, Gish RG, Everson GT. Model for end-stage liver disease (MELD) exception for polycystic liver disease. Liver Transpl 2006; 12(12 Suppl. 3): S110-S111.

  40. van Keimpema L, Nevens F, Adam R, Porte RJ, Fikatas P, Becker T, Kirkegard P, et al. Excellent survival after liver transplantation for isolated polycystic liver disease: An European Liver Transplant Registry study. Transplant International: Official Journal of the European Society for Organ Transplantation [Multicenter Study Research Support, Non-U.S. Gov’t] 2011; 24: 1239-45.

  41. Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL. Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database. Transplantation [Research Support, Non- U.S. Gov’t] 2006; 82: 1298-303.

  42. Chandok N, Uhanova J, Marotta P. Clinical outcomes of liver transplantation for polycystic liver disease: a single center experience. Ann Hepatol 2010; 9: 278-81.

  43. Pirenne J, Aerts R, Yoong K, Gunson B, Koshiba T, Fourneau I, Mayer D, et al. Liver transplantation for polycystic liver disease. Liver Transpl 2001; 7: 238-45.




2020     |     www.medigraphic.com